“These in vitro data demonstrating the efficacy of SAB-185 against the Delta and Lambda variants were produced to provide new insights into antibody binding to the SARS-CoV-2 spike variants, and as a ...
FDA findings from research published in bioRxiv using in vitro pseudovirus models confirm SAB-185 broadly neutralizes variants of concern Non-Solicitation This press release is not a proxy statement ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results